Sanara MedTech Inc. acquires Scendia Biologics, LLC for USD 7,360,000 (2022)

Deal facts

Buyer: Sanara MedTech Inc.
Target: Scendia Biologics, LLC
Deal value: USD 7,360,000
Announced: 5 July 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, shares, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 Jul 2022CompletedClosed
Sanara MedTech Inc. completes acquisition of Scendia Biologics, LLC
Item 1.01 Entry into a Material Definitive Agreement. On July 1, 2022, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Scendia Biologics, LLC, a Delaware limited liability company (“Scendia”), and Ryan Phillips (the “Seller”) pursuant to which, and in accordance with the terms and c
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Scendia Biologics by Sanara MedTech, a deal that closed in July 2022 for a total value of seven point three six million US dollars. This transaction sits firmly within the healthcare sector and represents a classic strategic move where a buyer seeks to integrate specific biological capabilities rather than simply buying a revenue stream. The structure is instructive for any SME founder watching the market, as it combines cash, shares, and an earn-out. This mix tells us the buyer wanted immediate control but remained cautious about the future performance of the target, a dynamic that often arises when the asset is high-potential but unproven at scale.

The inclusion of an earn-out is not merely a negotiation tactic; it is a risk allocation mechanism. By deferring part of the consideration until future milestones are met, Sanara MedTech protected itself against overpaying for technology that might not integrate smoothly or generate the expected returns. For the founder of Scendia, this structure likely meant accepting a lower upfront price in exchange for the chance to capture the full value if the business met its targets. In the US healthcare landscape, where regulatory pathways can be complex and product adoption slow, this approach is common. It shifts the burden of execution risk onto the original management team, ensuring they remain motivated post-closing to deliver the promised results.

We believe this deal highlights a critical reality for founders in the life sciences space: the headline price is rarely the whole story. The split between cash, equity, and contingent payments defines the actual risk profile of the exit. A deal valued at seven million dollars on paper could be worth significantly less if the earn-out conditions are too aggressive or if the share component underperforms. The SME founder must scrutinise the specific triggers for the deferred payment. Are they based on revenue, EBITDA, or regulatory approval? Without clarity on these mechanics, the final payout remains uncertain, regardless of the initial agreement.

Your immediate action this week should be to map out the specific performance milestones in any draft term sheet you hold. Do not accept vague language regarding the earn-out. Define the exact metrics, the measurement period, and the formula for calculation before you sign. If the buyer cannot agree to clear, objective targets, you must assume the deferred portion of the deal will not materialise and price your business accordingly today.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More strategic acquisition deals More from Sanara MedTech Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history